Follow
Johan Haux
Johan Haux
MD, PhD. Överläkare, Consultant in Medical Oncology, Skas Skövde
Verified email at vgregion.se - Homepage
Title
Cited by
Cited by
Year
Digitoxin is a potential anticancer agent for several types of cancer
J Haux
Medical hypotheses 53 (6), 543-548, 1999
2211999
Digitoxin medication and cancer; case control and internal dose-response studies
J Haux, O Klepp, O Spigset, S Tretli
BMC cancer 1 (1), 1-6, 2001
1792001
Regulation of APO-2 ligand/trail expression in NK cells—involvement in NK cell-mediated cytotoxicity
AC Johnsen, J Haux, B Steinkjer, U Nonstad, K Egeberg, A Sundan, ...
Cytokine 11 (9), 664-672, 1999
1321999
Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity
AE Medvedev, AC Johnsen, J Haux, B Steinkjer, K Egeberg, DH Lynch, ...
Cytokine 9 (6), 394-404, 1997
1191997
Digitoxin, in non toxic concentrations, induces apoptotic cell death in Jurkat T cells in vitro
J Haux, M Lain, ABL Marthinsen, T Strickert, S Lundgren
ZEITSCHRIFT FUR ONKOLOGIE 31, 14-14, 1999
481999
Digitoxin, in non-toxic concentrations, inhibits proliferation and induces cell death in prostate cancer cell lines
J Haux, O Solheim, T Isaksen, A Angelsen
Zeitschrift für Onkologie 32 (01), 11-16, 2000
372000
Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1).
KJ Labori, SO Bratlie, C Biörserud, B Björnsson, E Bringeland, N Elander, ...
Journal of Clinical Oncology 41 (17_suppl), LBA4005-LBA4005, 2023
332023
The role of interleukin-2 in regulating the sensitivity of natural killer cells for Fas-mediated apoptosis
J Haux, AC Johnsen, B Steinkjer, K Egeberg, A Sundan, T Espevik
Cancer Immunology, Immunotherapy 48, 139-146, 1999
271999
Digitalis; impinges on more than just the (ion-) pump
J Haux
Medical hypotheses 59 (6), 781-782, 2002
152002
The dynamics of cell proliferation
JF Moxnes, J Haux, K Hausken
Medical hypotheses 62 (4), 556-563, 2004
132004
Infection and cancer
J Haux
The Lancet 358 (9276), 155-156, 2001
122001
Digitoxin sensitizes malignant breast cancer cells for radiation in vitro
J Haux, ABL Marthinsen, M Gulbrandsen, AS Alfredsen, H Johansen, ...
ZEITSCHRIFT FUR ONKOLOGIE 31, 61-65, 1999
111999
SOULMATE: the Swedish study of liver transplantation for isolated colorectal cancer liver metastases not suitable for operation or ablation, compared to best established …
V Reivell, H Hagman, J Haux, C Jorns, P Lindnér, H Taflin
Trials 23 (1), 831, 2022
92022
Digitoxin has specific properties for potential use to treat cancer and inflammatory diseases
J Haux
Research and Reviews on Healthcare: Open Access Journal 2, 2018
92018
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial
KJ Labori, SO Bratlie, B Andersson, JH Angelsen, C Biörserud, ...
The Lancet Gastroenterology & Hepatology 9 (3), 205-217, 2024
22024
ISO-005; An open-label, multiple-site, dose cohort, phase I/II study in patients with stage IV colorectal cancer.
HA Taflin, Y Wettergren, E Odin, J Haux, B Gustavsson, GU Carlsson
Journal of Clinical Oncology 35 (4_suppl), TPS811-TPS811, 2017
22017
A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer
G Carlsson, A Koumarianou, TK Guren, J Haux, P Katsaounis, ...
ESMO open 7 (5), 100589, 2022
12022
Inflammasomes can be formed in pancreatic cancer cells, and NLRP3 inflammasome associated genes are up-regulated in primary pancreatic tumors
H Lindholm, M Herring, M Faresjö, J Haux, F Szekeres, K Ejeskär
2023
Digitoxin treatment affects choline metabolism in pancreatic cancer cells
H Lindholm, B Ulfenborg, M Faresjö, J Haux, K Ejeskär, F Szekeres
2023
STUDY PROTOCOL
V Reivell, H Hagman, J Haux, C Jorns, P Lindnér, H Taflin
2022
The system can't perform the operation now. Try again later.
Articles 1–20